41 results on '"Fricke, Jeremy"'
Search Results
2. Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
3. RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer
4. Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach
5. Early-Stage Lung Cancer in the Era of Precision Oncology: From Immunotherapy to Targeted Therapy
6. A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report
7. Clinical Features Associated with Immune Checkpoint Inhibitor Nephritis: A Single-Center Clinical Case Series
8. Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
9. MET receptor in oncology: From biomarker to therapeutic target
10. Clinical Network Systems Biology: Traversing the Cancer Multiverse
11. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
12. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma
13. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
14. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
15. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
16. Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
17. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
18. Book Review: Tyler D. Mayfield, Father Abraham’s Many Children: The Bible in a World of Religious Difference
19. Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
20. Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report
21. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
22. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
23. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
24. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
25. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer
26. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
27. Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach.
28. Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
29. Abstract 3300: Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
30. Abstract 2037: Association of molecular heterogeneity and actionable mutations with survival in lung cancer
31. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
32. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling
33. Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer.
34. Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer.
35. Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach
36. Precision medicine and actionable alterations in lung cancer: A single institution experience
37. Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies.
38. White gods
39. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
40. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations.
41. MET receptor in oncology: From biomarker to therapeutic target.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.